Enhanced CGT R&D & Manufacturing at Reduced Cost for Increased Market Access
Cell and gene therapy are novel therapeutics that have attracted much attention amongst the global biomedical sectors for the treatment of diseases and physiological conditions due to their promising potential in addressing unmet medical needs.
There is a strong potential in the CGT industry growth from the drivers of robust cell & gene therapies in the pipeline, emerging numbers of CMOs offering vector manufacturing services, increase in strategic acquisitions as well as regulatory support for cell and gene therapy products. With the success of two cell therapies for treating aggressive B-cell lymphomas — Novartis’s Kymriah and Gilead’s Yescarta — and one ex vivo gene therapy, Bluebird Bio’s Zyn- teglo, and more products in the pipeline to come, the blooming cell and gene therapy new modalities will transform the traditional treatment method.
Come to you as a part of the Cell and Gene Therapy World Series, the Cell & Gene Therapy World Summit 2023 brings together CGT players together to discuss and debate the best practices of CGT R&D and Manufacturing while serving as a platform to showcase your latest innovation to the CGT industry leaders!
Explore different approaches of preclinical and clinical development such as proof-of-concept studies and extensive clinical research along with the latest developments in safety and efficacy, designing and implementing early-phase clinical trials and strategies for patient selection and recruitment. Learn about the pivotal role these processes play in ensuring that cell and gene therapies can be made available to patients as safe and effective treatment options.
Gain the current insights on cell and gene therapy manufacturing, strategies to streamline the manufacturing processes for improved efficiency and reduced cost along with techniques in cell expansion, cell culture and vector production. Find out how these practices accelerate the translation of scientific advancements into robust and reliable manufacturing processes for cell and gene therapies.
Review our collection of case studies highlighting significant achievements in the field of cell and gene therapy from across Europe, such as the development and commercialization of Strimvelis, and the clinical outcomes of Kymriah. These case studies will provide valuable insights for researchers, clinicians, and industry professionals engaged in the development and application of these transformative therapies.
Delve into our interactive and informative roundtable discussions which will feature topics from the Lessons from Cell and Gene Therapy Clinical Trials, Technology and Innovation in Cell and Gene Therapy, Overcoming Challenges in Commercialization along with Collaboration and Partnerships, Addressing Safety and Efficacy Concerns and The Future of Cell and Gene Therapy to name a few. Facilitated by industry experts, our discussions will provide an opportunity for delegates and speakers to network and connect while gaining the latest and more relevant insights into the cell and gene therapy industry.
Identify the advancements in gene editing tools, such as CRISPR/Cas9, that have significantly enhanced the precision and effectiveness of treatments by allowing for precise gene corrections, insertions, or deletions, offering unprecedented opportunities to address genetic diseases at their root cause and the advancements in vector design that have improved the delivery of therapeutic genes to target cells.
Learn about the novel therapies that aim to overcome existing limitations and expand the scope of treatment options for various diseases. Cutting-edge technologies, RNA-based therapeutics and advanced cell engineering are a few of the key innovations included, that are paving the way for more precise and targeted interventions. Find out how these next-generation treatments are poised to provide personalized, durable, and curative solutions for patients, offering hope for improved clinical outcomes and transforming the landscape of healthcare.
Limited Super (By 22nd Feb 2024)
£ 850
Limited Special (By 19th April 2024)
£ 1,050
Early Bird (By 10th May 2024)
£ 1,250
Standard Price
£ 1,450
Limited Group Packages
Limited Super (By 22nd Feb 2024)
£ 2,050
Limited Special (By 19th April 2024)
£ 2,250
Early Bird (By 10th May 2024)
£ 2,450
Standard Price
£ 2,650
Group Discount for Solution Providers & General Public: Buy 3 and get 10% off, Buy 5 get 20% off, Buy 6 and above, get 25% off
Biopharma in Australia and New Zealand is a burgeoning sector, driven by robust research and innovation. The region boasts a strong biotechnology infrastructure, fostering collaborations between academia and industry.
Australia and New Zealand's biopharma companies are actively engaged in developing novel therapies for various diseases, contributing to the global healthcare landscape. Supported by favorable regulatory environments, these nations are attracting investments and establishing themselves as significant players in the biopharmaceutical industry.
At the 2nd Australia Biologics Festival conference, we propose to “feature” the top research work done by the biopharma industry and the academic & research institutes and solution providers from the ANZ region and beyond. The poster presentation will be viewed by 300+ Biopharma industry professionals from top notch biopharma companies.
Some suggested themes for the posters include, but are not limited to:
Abstracts & Poster PDF Submission Guidelines:
On-site Poster Presentation Guidelines:
Interested in giving a presentation? Enquire now...
Biopharma in Australia and New Zealand is a burgeoning sector, driven by robust research and innovation. The region boasts a strong biotechnology infrastructure, fostering collaborations between academia and industry.
Australia and New Zealand's biopharma companies are actively engaged in developing novel therapies for various diseases, contributing to the global healthcare landscape. Supported by favorable regulatory environments, these nations are attracting investments and establishing themselves as significant players in the biopharmaceutical industry.
At the 2nd Australia Biologics Festival conference, we propose to “feature” the top research work done by the biopharma industry and the academic & research institutes and solution providers from the ANZ region and beyond. The poster presentation will be viewed by 300+ Biopharma industry professionals from top notch biopharma companies.
Some suggested themes for the posters include, but are not limited to:
Abstracts & Poster PDF Submission Guidelines:
On-site Poster Presentation Guidelines:
Interested in giving a presentation? Enquire now...
IMAPAC is the go-to holistic producer of live events, biopharma data and digital marketing solutions for the global biopharmaceutical industry.
© 2023 Imapac. All rights reserved. Trade marks are owned by or licensed to imapac.
